These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32396018)

  • 1. Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.
    Georgakopoulos JR; Vender R; Yeung J
    J Cutan Med Surg; 2020; 24(4):418-419. PubMed ID: 32396018
    [No Abstract]   [Full Text] [Related]  

  • 2. Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
    Armesto S; González Vela C; González López MA
    Dermatol Ther; 2020 Jul; 33(4):e13618. PubMed ID: 32424891
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
    [No Abstract]   [Full Text] [Related]  

  • 4. Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):424-425. PubMed ID: 32475151
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
    Mugheddu C; Pizzatti L; Sanna S; Atzori L; Rongioletti F
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e376-e378. PubMed ID: 32385859
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
    Melis D; Mugheddu C; Sanna S; Atzori L; Rongioletti F
    Dermatol Ther; 2020 Jul; 33(4):e13722. PubMed ID: 32475036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.
    Georgakopoulos JR; Mufti A; Vender R; Yeung J
    J Am Acad Dermatol; 2020 Oct; 83(4):1212-1214. PubMed ID: 32679279
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto.
    Seung Kim JH; Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(5):534-535. PubMed ID: 33023343
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologics, spondylitis and COVID-19.
    Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
    Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19 in an elderly patient treated with secukinumab.
    Di Lernia V; Bombonato C; Motolese A
    Dermatol Ther; 2020 Jul; 33(4):e13580. PubMed ID: 32406078
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
    Megna M; Fabbrocini G; Marasca C
    Int J Dermatol; 2020 Sep; 59(9):1144-1145. PubMed ID: 32710548
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel clinical set-up for examining healthy dermatology outpatients during the COVID-19 pandemic.
    Gupta S; Jangra RS; Gujrathi AV; Mahendra A; Singla R; Sharma A; Gupta S
    Clin Exp Dermatol; 2020 Aug; 45(6):749-750. PubMed ID: 32304576
    [No Abstract]   [Full Text] [Related]  

  • 13. Managing chronic pain patients at the time of COVID-19 pandemic.
    Coluzzi F; Marinangeli F; Pergolizzi J
    Minerva Anestesiol; 2020 Aug; 86(8):797-799. PubMed ID: 32400999
    [No Abstract]   [Full Text] [Related]  

  • 14. Virtual conferences of dermatology during the COVID-19 pandemic.
    Goldust M; Shivakumar S; Kroumpouzos G; Murrell DF; Rudnicka L; Jafferany M; Navarini AA
    Dermatol Ther; 2020 Jul; 33(4):e13774. PubMed ID: 32506609
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic.
    Kaye L; Theye B; Smeenk I; Gondalia R; Barrett MA; Stempel DA
    J Allergy Clin Immunol Pract; 2020; 8(7):2384-2385. PubMed ID: 32371047
    [No Abstract]   [Full Text] [Related]  

  • 16. Dermatology and COVID-19.
    Shinkai K; Bruckner AL
    JAMA; 2020 Sep; 324(12):1133-1134. PubMed ID: 32960253
    [No Abstract]   [Full Text] [Related]  

  • 17. Publishing in the time of pandemic: Editorial policy of a dermatology journal during COVID-19.
    Panda S
    Indian J Dermatol Venereol Leprol; 2020; 86(4):337-340. PubMed ID: 32525104
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 pandemic.
    Moock M; Mello PMVC
    Rev Bras Ter Intensiva; 2020 Mar; 32(1):1. PubMed ID: 32401986
    [No Abstract]   [Full Text] [Related]  

  • 19. Prioritizing specialized children's surgery in Canada during the COVID-19 pandemic.
    Skarsgard ED;
    CMAJ; 2020 Oct; 192(41):E1212-E1213. PubMed ID: 32873542
    [No Abstract]   [Full Text] [Related]  

  • 20. Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?
    Shanshal M
    J Drugs Dermatol; 2020 Apr; 19(4):436. PubMed ID: 32401460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.